Digestive Diseases

14.8

Million adults diagnosed with ulcers

32.3

Million visits to clinics due to digestive diseases

6.1%

Of adults globally diagnosed with ulcers


SRS is adopting a multidisciplinary approach to Digestive Disorders and Diseases.

 
Digestive disorders and diseases significantly affect millions of people worldwide, inducing a highly significant economic impact comprising health care costs and work absenteeism, in addition to patient’s decreased quality of life. Organic diseases include gastroesophageal reflux disease, Helicobacter pylori infection, and colorectal cancer. Whereas functional digestive disorders include, Functional Dyspepsia, Irritable Bowel Syndrome (IBS), functional constipation.


Unique solutions to make a real impact

Sunwic® 3-in-1

To tackle
Functional Dyspepsia and Irritable Bowel Syndrome (IBS)
Ulcerative Colitis

Prebiotic, Probiotic and Colostrum

Sunwic 3-in-1 is a synbiotic product with colostrum. Ingredients all aid a stomach in distress. Sunwic’s dietary guar bean fiber is nourishment for the stomach’s healthy bacteria. The ingredients in this product are supported by 455 published studies!

With Sunwic 3-in-1, you get three important and highly concentrated nutrients all in the same product. Sunwic 3-in-1 can be taken together with antibiotics. After discontinued use of Sunwic 3-in-1, continue with Sunwic dietary fiber.

These unique vegetable fibers feed the stomach’s healthy bacteria, promoting a healthy stomach environment. This helps the stomach’s natural function and digestion. The colostrum adds a natural layer of protection and nourishment.

Pyloclean™

To tackle
H. pylori Infections

In 2017, the World Health Organization (WHO) designated clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effects.

Non-Viable Lactobacillus reuteri DSMZ 17648 (Pyloclean™): A New Approach to Helicobacter pylori control in humans

For the first time, spray-dried cells of L. reuteri DSMZ17648 have been used in a human study and results confirm the potential of Pyloclean™ as a novel way to reduce the load of H. pylori.

With the resistance of H. pylori to antibiotics reaching alarming levels worldwide, and hampering the efficacy of treatments, Pyloclean™ represents a very interesting alternative thanks to a unique mode of action that does not lead to resistance.

Livenciale

To tackle
Cirrhosis of the Liver

The active ingredient of Livenciale is ‘essential phospholipids’. In cirrhosis, the structure of cell membranes and the function of enzyme systems for liver diseases are violated. With a deficiency of phospholipids, there is a disturbance in fat metabolism, which leads to fatty liver disease. Due to its pharmacological properties, Livenciale medicine eliminates these disorders and increases the detoxification capacity of the liver and thus normalizes its function.

Interested?
Let us know.



contact us

Driven to tackle the biggest problems with novel solutions and excellent partners


As part of our ongoing fight against this disease, we continue to explore novel, evidence-based products and concepts; working with like-minded inventors and partners to get the right treatments to the people in need, when they need them.

Currently, we are focusing on products in the following areas.

  • Gastritis
  • Inflammatory Bowel Disease (IBD)
  • Peptic Ulcer Disease

Connect with us
To find out more about
Our pipeline



contact us
.